MedTrace Logo

Understanding Immunity Persistence After Adolescent MenC Vaccination

NCT01459432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2015-11-09

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age. Does seroprotection persist beyond teenage years and into the early twenties? This is the age group which is most likely to carry the organism and to transmit it to other members of the population. If a booster dose of MenC vaccine given to adolescents does produce protective levels of antibody which persist into early adulthood, this would strengthen the case for such a booster to be added to the UK routine immunisation schedule, to reduce the risk of a resurgence of the disease in the future.

Conditions

  • Antibody Persistance After Booster Dose of Men C Vaccine

Interventions

OTHER

Venepuncture and blood sample collection.

Venepuncture and blood sample collection.

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
23 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459432 on ClinicalTrials.gov